Allogene Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
Allogene Therapeutics, Inc. (ALLO) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2026-03-12
- Allogene Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, amount for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Allogene Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was $443.00K, a 84.58% increase from fiscal 2023.
- Allogene Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was $240.00K, a 85.65% decline from fiscal 2022.
- Allogene Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, amount for fiscal 2022 was $1.67M, a 8705.26% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 1 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 | ||
| 2024-12-31 | $443.00K 10-K · filed 2026-03-12 | $209.00K 10-K · filed 2025-03-13 | |
| 2023-12-31 | $240.00K 10-K · filed 2025-03-13 | $550.00K 10-K · filed 2024-03-14 | |
| 2022-12-31 | $1.67M 10-K/A · filed 2024-03-14 | $128.00K 10-K · filed 2023-02-28 | |
| 2021-12-31 | $19.00K 10-K/A · filed 2024-03-14 | -$692.00K 10-K · filed 2022-02-23 | |
| 2020-12-31 | $171.00K 10-K/A · filed 2024-03-14 | -$14.00K 10-K · filed 2021-02-25 | |
| 2019-12-31 | $1.14M 10-K · filed 2022-02-23 | $1.14M 10-K · filed 2020-02-27 | |
| 2018-12-31 | $438.00K 10-K · filed 2021-02-25 | ||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |